Perhaps no area of pharmacology has progressed further or faster than that of anticancer drugs. With this concise and informative resource, you'll explore the full spectrum of anticancer drug evolution -- from research and development, through clinical trials, to licensure and utilization.

There are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes of anticancer drug development, creating a single indispensable reference that covers all the steps from the identification of cancer-specific molecular targets to screening techniques and the development and validation of bioanalytical methods to clinical trial design and all phases of clinical trials. The authors have included new material on phase 0 trials in oncology, organ dysfunction trials, drug formulations and their impact on anticancer drug PK/PD including strategies to improve drug delivery, pharmacogenomics and cancer therapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer. Authoritative and up-to-date, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition provides in one comprehensive and highly practical volume a detailed step-by-step guide to the successful design and approval of anticancer drugs. Road map to anticancer drug development from discovery to NDA submission Discussion of molecular targets and preclinical screening Development and validation of bioanalytical methods Chapters on clinical trial design and phase 0, I, II, III clinical trials Pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacogenetics of anticancer agents Review of the drug development process from both laboratory and clinical perspectives New technological advances in imaging, high throughput platforms, and nanotechnology in anticancer drug development

Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe the arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.

This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.

This timely desk reference focuses on marine-derived bioactive substances which have biological, medical and industrial applications. The medicinal value of these marine natural products are assessed and discussed. Their function as a new and important resource in novel, anticancer drug discovery research is also presented in international contributions from several research groups. For example, the potential role of Spongistatin, Apratoxin A, Eribulin mesylate, phlorotannins, fucoidan, as anticancer agents is explained. The mechanism of action of bioactive compounds present in marine algae, bacteria, fungus, sponges, seaweeds and other marine animals and plants are illustrated via several mechanisms. In addition, this handbook lists various compounds that are active candidates in chemoprevention and their target actions. The handbook also places into context the demand for anticancer nutraceuticals and their use as potential anti-cancer pharmaceuticals and medicines. This study of advanced and future types of natural compounds from marine sources is written to facilitate the understanding of Biotechnology and its application to marine natural product drug discovery research.

A practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs.

Anticancer drugs refer to drugs that are used for treating cancerous or malignant diseases. They are classified into several categories, including antimetabolites, hormones, alkylating agents and natural products. Preclinical research, clinical research and post-clinical research are the three primary steps in the development of a novel drug. Clinical trial evaluation, in vivo confirmation, and in vitro cytotoxicity on cancer cells are the major assessment methods used while creating an anticancer drug. The evaluation of cytotoxicity towards cancer cell lines is a popular method for discovering anticancer agents. New cancer drugs can be discovered in a variety of ways including testing of animals, plants and fungi, understanding the chemical structure of a drug target, unintentional discovery, developing drugs that are similar to existing drugs, and researching the biology of cancer cells. This book unravels the recent studies on anticancer drug discovery and development. Those in search of information to further their knowledge will be greatly assisted by it.

This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.

Protocol Handbook for Cancer Biology brings together a comprehensive collection of the methods used for cancer assessment, diagnostics, and therapeutics. Various protocols are discussed along with alternative strategies, including the advantages and limitations of techniques that have been used in labs globally. These protocols are presented by cancer biology experts based on their real-world experience. The protocols in this book will be a valuable resource for cancer researchers and graduate students, who can utilize the techniques described to conduct research more efficiently and successfully. Presents comprehensive protocols used for cancer assessment, diagnostics, and therapeutics all in one place Encompasses alternative strategies considering the requirements of the end user and taking into consideration diverse research settings Discusses limitations and advantages of each method in experimental design and execution, thus saving time during the research process

Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs, Second Edition is a visually engaging reference detailing the essential basic and clinical science of all approved, effective, and life-prolonging drug therapies in oncology. Now with a greater emphasis on clinical context, application, and management in each chapter, this significantly revised edition provides both early-career and seasoned clinicians with a practical, bench-to-bedside approach and patient-oriented guide. The book provides detailed coverage of the major advances in cancer pharmacology at the forefront of our standards of care for solid tumors and hematologic malignancies, in addition to the basic science that is directly necessary and applicable when at the patient’s bedside. Everything from traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents is explored, in addition to a new chapter covering pharmacogenomics. Accompanied by elegant illustrations, each chapter details the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic and molecular properties of the various agents, and their mechanisms of action. The book covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Thoroughly updated to include new FDA-approved treatments and applications, and written by leading experts in cancer pharmacology, this second edition continues to be a “must have” for anyone involved in the basic, translational, or clinical aspects of oncology and hematology, including clinicians, pharmacists, nurses, and trainees. Key Features: Over 150 beautiful illustrations depict structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents Contains more than 160 high-yield hematology and oncology board-style chapter review questions (more than double the previous edition) with descriptive rationales Describes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work, and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other treatment modalities Thoroughly updated and revised chapters cover new FDA drug approvals, disease-site indications, clinical applications and management of drug-to-drug interactions, and toxicities Discusses challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatments Provides important pharmacotherapy context with clinical pearls in each chapter that help support a patient-oriented, bedside approach